Download Information Leaflet - Breast Cancer

CLINIPORATOR
CLINIPORATOR
LEADING CLINICAL ELECTROPORATION
Conclusions
Treatment with Electrochemotherapy is
appropriate for patients suffering with
recurrent cutaneous disease. The best response
is obtained when the tumour is less than 3cm
in diameter, is sensitive to endocrine treatment
and the patient has lesions that are localised
close to the scar of the primary tumour. Local
control of the disease has an important effect
on quality of life and improves life expectancy.
Electrochemotherapy can be considered
an effective addition to the cancer treatment
armamentarium.
LEADING CLINICAL ELECTROPORATION
CLINIPORATOR
LEADING CLINICAL ELECTROPORATION
References
1. Spratt DE et al. Efficacy of Skin-Directed Therapy for Cutaneous
Metastases From Advanced Cancer: A Meta-Analysis. JCO. 2014.
2. Benevento R et al. Electrochemotherapy of cutaneous metastastes from
breast cancer in elderly patients: a preliminary report. BMC Surgery
2012, 12(Suppl 1):S6.
3. Campana LG et al. The activity and safety of electrochemotherapy in
persistent chest wall recurrence from breast cancer after mastectomy:
a phase-II study. Breast Cancer Res Treat. 2012 Aug;134(3):1169-78.
4. Campana LG et al. Bleomycin electrochemotherapy in elderly
metastatic breast cancer patients: clinical outcome and management
considerations. J Cancer Res Clin Oncol 2014
The role of
Electrochemotherapy in
breast cancer for patients
with local recurrence or
cutaneous metastases
5. Larkin JO et al. Electrochemotherapy, aspects of preclinical
development and early clinical experience. Ann Surg 2007;245:
469-479.
6. Madero MV et al. Electrochemotherapy for treatment of skin and soft
tissue tumours. Update and defi nition of its role in multimodal therapy.
Clin Transl Oncol (2011) 13:18-24.
7. Marty M et al. Electrochemotherapy – an easy, highly effective and safe
treatment of cutaneous and subcutaneous metastases. Results of ESOPE
(European Standard Operating Procedures of Electrochemotherapy)
study. EJC 2006;Suppl 4:3-13.
Further reading
•
Mali B et al. Antitumor effectiveness of electrochemotherapy:
a systematic review and meta-analysis. Eur J Surg Oncol. 2013;
39(1):4-16.
•
Matthiessen LW et al. Management of cutaneous metastases using
electrochemotherapy. Acta Oncologica, 2011; 50: 621–629.
•
Mir LM et al. Standard operating procedure of the electrochemotherapy:
instructions for the use of bleomycin or cisplatin administered either
systemically or locally and electric pulses delivered by the Cliniporator by
means of invasive or non-invasive electrodes. EJC 2006;Suppl 4:14-25.
•
Sersa G, et al. Electrochemotherapy of chest wall breast cancer recurrence.
Cancer Treatment Reviews 38 (2012) 379–386.
HEADQUARTERS
IGEA S.p.A.
Via Parmenide, 10/A
41012 Carpi (MO) ITALY
Phone +39 059 699600 r.a.
www.igeamedical.com
[email protected]
IGEA Breast Leaflet V2.indd 1
GERMANY
IGEA GmbH
www.igeamedical.de
[email protected]
GREAT BRITAIN
IGEA UK
Phone +44 (0)1279 874535
www.igeamedical.co.uk
[email protected]
A simple solution
for challenging situations
03/02/2015 16:33
CLINIPORATOR
The role of Electrochemotherapy in breast cancer for patients
with local recurrence or cutaneous metastases
Rationale
With advances in the treatment of metastatic cancer,
patients are living longer and are more likely to
experience the symptoms of advanced disease such
as cutaneous metastases (CM). CM can cause significant
morbidity including infection, bleeding, odour
and pain. It has been demonstrated that amongst
women with advanced or recurrent breast cancer,
CM were associated with the greatest effect on
quality of life. Systemic therapy alone often has
limited efficacy in CM.(1)
Electrochemotherapy
for breast cancer patients
Several clinical studies demonstrate the efficacy and
safety of Electrochemotherapy (ECT) treatment with the
CLINIPORATOR in breast cancer patients. [Table 1]
CLINIPORATOR
LEADING CLINICAL ELECTROPORATION
LEADING CLINICAL ELECTROPORATION
NICE guidelines
How effective is
Electrochemotherapy?
The effectiveness of Electrochemotherapy is determined
by the following factors:
• Number and size of the lesions
• Anatomical location
• Sensitivity to endocrine treatment
These considerations help to define which eligible
patients will respond the best to the treatment and
who will have good local tumour control and better
survival overall.
Patients who show the best
response to Electrochemotherapy
NICE published guidance on Electrochemotherapy
in March 2013, saying that it may reduce symptoms
and improve quality of life for appropriately selected
patients. NICE has said that this procedure can be:
‘offered routinely as a palliative treatment option
for people with metastases in the skin from tumours
of non-skin origin or melanoma...the procedure may
reduce symptoms and improve quality of life for
people with disease that cannot be treated with, or
doesn’t respond to, other treatments’.
Treat earlier for better results
TM
Clinical Experience of
Electrochemotherapy
on breast cancer
Benevento R,
BMC Surg, 2012(2)
Campana LG,
Breast Cancer Res Treat, 2012(3)
Campana LG,
JCRCO, 2014(4)
Larkin JO,
Ann Surg, 2007(5)
Madero VM,
Clin Trans Oncol, 2011(7)
Marty M,
EJC, 2006(8)
TOTAL
Patients
OR
[%]
Figure a: Pre-treatment
Figure b: After 2 months
(Larkin JO et al., Ann Surg, 2007)
12
92
35
91
55
87
14
79
25
72
14
95
155
87
Table 1: Studies with Electrochemotherapy on recurrences and metastases
from breast cancer.
IGEA Breast Leaflet V2.indd 2
No visceral
metastases
Positive
response
to endocrine
therapy
Close to
the scar
of primary
tumour
<10 lesions
ELECTIVE
PATIENT
Results from recent clinical studies have indicated that
patients with ten or fewer skin metastases, which are
smaller than 3cm in diameter, are likely to have a positive
response following treatment with Electrochemotherapy.
Palliative effect
Ø<3cm
Figure 1: Patients who will respond best to treatment with
Electrochemotherapy (ECT).
In addition to the patients described in Figure 1, those
patients requiring palliation of large ulcerated bleeding
lesions can be treated with Electrochemotherapy. This
treatment can improve quality of life and provide
symptomatic relief, including immediate cessation of
bleeding, decreased odour and reduction in ulceration.
03/02/2015 16:33